Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer Spring Investor Conference March 16 Will Stress 2004 Financial Upturn

This article was originally published in The Pink Sheet Daily

Executive Summary

Restructuring is seen as a key factor in Bayer's improved performance. Its U.S. oncology business and ex-U.S. Levitra promotion are among likely topics for updates at the investor meeting.

You may also be interested in...

Bayer Expands Levitra Marketing Rights Outside U.S.

Bayer purchases GlaxoSmithKline's co-promotion rights to the erectile dysfunction agent "in most major markets outside the U.S.," nearly four months after selling the U.S. marketing rights to its primary care products, including Levitra, to Schering-Plough.

Bayer R&D, Production Job Cuts Finalize Restructuring

Company plans to eliminate 110 jobs at West Haven, Conn. facility and 440 in Germany, resulting in cost savings of over $170 mil. R&D projects in anti-infectives and urology could be out-licensed.

"Bayer-ly" An Rx Company? Viadur Is Focus Of New Bayer Oncology Unit

Bayer is setting up a new oncology division in West Haven, Conn. as the focus of its U.S. prescription drug business following a Sept. 13 licensing deal with Schering-Plough





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts